key: cord-0324414-6ydc6nko authors: Hernandez-Teran, A.; GarciaDiego, P.; Villanueva-Reza, M.; Boukadida, C.; Taboada, B.; Porras, E.; Ahumada-Topete, V.; Tapia Diaz, K.; Matias-Florentino, M.; Perez-Garcia, M.; Avila-Rios, S.; Mejia-Nepomuceno, F.; Serna-Munoz, R.; Juarez-Hernandez, F.; Jimenez-Corona, M. E.; Becerril-Vargas, E.; Barreto, O.; Martinez-Orozco, J. A.; Perez-Padilla, R.; Arias, C. F.; Vazquez-Perez, J. A. title: Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Vaccinated and Unvaccinated Patients in Mexico City date: 2022-05-09 journal: nan DOI: 10.1101/2022.05.06.22274772 sha: ca6ef366b4ec66ea2a77bc56eb628eccabd564e0 doc_id: 324414 cord_uid: 6ydc6nko Background: Coronavirus disease 2019 (COVID-19) vaccines are very effective at protecting against severe disease and death. However, the impact of the vaccine used, viral variants, and host factors on disease severity in vaccinated individuals remain poorly understood. Here we compared COVID-19 clinical presentations and outcomes in vaccinated and unvaccinated patients in a tertiary hospital in Mexico City. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants were also determined to study their potential impact on disease severity. Methods: From March to September 2021, clinical and demographic characteristics were obtained from 1,014 individuals with a documented SARS-CoV-2 infection, and viral variants were identified in a subset of 386 patients. We compared three groups of patients: 1) unvaccinated, 2) partially vaccinated, and 3) fully vaccinated, stratifying by age groups (<30 years, 31-60 years, and > 61 years) on the clinical outcomes, and including in-hospital mortality. We fitted different multivariate statistical models to evaluate the impact of vaccination status, SARS-CoV-2 lineages, vaccine types, and clinical parameters. Results: 1,014 patients were included, with 11% being outpatients and 88% hospitalized. Most hospitalized patients were unvaccinated. In patients over 61 years old, mortality was significantly higher in unvaccinated compared to fully vaccinated individuals. In patients aged 31 to 60 years, vaccinated patients were more likely to be outpatients (46%) than unvaccinated individuals (6.1%). The percentage of critical patients over 61 years was higher in unvaccinated than vaccinated individuals (75% vs. 56%, p < 0.001). We found immune disease (OR: 3.12, 95% CI: 1.09-8.34, p = 0.02) and age above 61 years old (OR: 3.51, 95% CI: 2.3-5.2, p = 5.9e-10) as risk factors. While fully vaccination was found as the most protective factor against in-hospital death (OR: 0.25, 95% CI: 0.12-0.46, p = 2.89e-05). Conclusions: This study suggests that vaccination and particularly full vaccination is essential to reduce mortality in a comorbid population such as that of Mexico. When analyzing the presence of comorbidities and advanced ages as risk factors, complete vaccination was the most significant protective factor against death by COVID-19. We found no strong association between SARS-CoV-2 lineages or vaccine type and disease severity. Importantly, COVID-19 vaccines have been shown to be effective at preventing severe 95 disease and death even in patients with comorbidities [12] . As a result, fully vaccinated 96 persons are less likely to experience severe disease or death than unvaccinated persons with 97 the same medical conditions [13] . Nonetheless, vaccines are less effective at protecting 98 from SARS-CoV-2 infections, and this partial protection seems to wane after a few months, 99 leading to infections in vaccinated individuals (breakthrough infections) [14] . For all patients, demographic data, clinical symptoms, laboratory, radiology data, and 120 outcome-related information were obtained from electronic medical records. Clinical 121 management was performed according to the standards of care and attending physicians. 122 Follow-up went from the time of admission for up to 28 days. This study was reviewed and 123 approved by the Science, Biosecurity, and Bioethics Committee of the Instituto Nacional de 124 Enfermedades Respiratorias (B-10-20). In addition, the Institution requested informed 125 consent for the recovery, storage, and use of biological remnants for research purposes. 126 127 Oropharyngeal and/or nasopharyngeal swabs were collected, and the diagnosis was made 129 using validated RT-qPCR protocols for SARS-CoV-2 RNA detection, approved by the 130 Complete genome sequencing 137 Viral nucleic acid extraction was performed using a MagNa Pure L.C. 2-0 system (Roche, 138 Indianapolis, OH, USA) or QIAamp viral RNA Minikit (Qiagen, Hilden Germany). 139 Libraries for whole-genome sequencing of SARS-CoV-2 were generated using the protocol 140 developed by the ARTIC Network (https://artic.network/2-protocols.html) or a long-141 amplicon-based method [18] . Libraries were sequenced on a MiSeq sequencing platform 142 using a 2x150-cycle or a NextSeq 500 platform using 2x150-cycle mid-output kits to obtain 143 using an ABI Prism 3500 Genetic Analyzer (Life Technologies) and were assembled using 156 To perform a phylogenetic analysis, we analyzed only samples with complete genomes of 161 hospitalized and ambulatory patients from our cohort (N= 311 To evaluate the impact on clinical outcomes, we divided our cohort into three groups: 1) 175 unvaccinated: defined as those patients who had never received a SARS-CoV-2 vaccine; 2) 176 partially vaccinated: defined as those patients who had not yet completed the standard 177 vaccination schedule (depending on the vaccine) or had received the last dose less than 14 178 days before symptom onset; and 3) fully vaccinated: defined for those patients who had 179 already completed the vaccination schedule and with more than 14 days after the last dose. 180 As advanced age is a significant driver of severe COVID-19 [22]; we categorized patients 181 into three groups: <30 years old, 31-60 years old, and > 61 years old. In addition, the 182 severity of the disease was categorized according to the NIH COVID-19 treatment 183 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. We compared the distribution of COVID-19 severity, severity indexes, O 2 requirement, and 281 laboratory parameters among patients with different vaccination status and age ( Fig. 1-2) . 282 Overall, due to the timing of the vaccination campaign in Mexico, most of the vaccinated 283 patients were received from June to August, while unvaccinated patients arrived at the 284 hospital in equal proportion during the sampling months (Suppl. Fig. S1 ). 285 In general, we found that a large proportion of patients were classified either as severe or 287 critical, regardless of age and vaccination status (Fig. 1A) . Nonetheless, the highest 288 proportion of patients with mild disease was found in fully vaccinated patients under 30 289 years old (Suppl. Table S1 , Chi-square test p < 0.001), while the highest proportion of 290 critical patients were unvaccinated older than 61 years old (Suppl. Table S1 , Chi-square test 291 p < 0.001). It is essential to highlight that for older patients (>61 years) the vaccination 292 status seems to be associated with less disease severity, reducing the number of critical 293 patients (Suppl. Table S1, unvaccinated against vaccinated patients; Chi-square test p = 294 0.001) and slightly increasing the number of patients with mild disease in the vaccinated 295 groups (Suppl. Table S1 , Chi-square test p < 0.002). Furthermore, we do not find statistical 296 differences in the most commonly used ICU scales ( Fig. 1B ) (SOFA and APACHE II). 297 Nonetheless, we detected that, although most of the patients were subjected to mechanical 298 ventilation, the highest proportion of intubated patients was in the unvaccinated group (Fig. 299 1C) . 300 301 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274772 doi: medRxiv preprint Finally, we also investigated whether patients with different vaccination status and age 302 differ in laboratory parameters (Fig. 2) . The most remarkable differences were found in the 303 unvaccinated group, particularly when comparing patients <30 years with >61 years. For 304 instance, we found that, regardless of the vaccination status, patients older than 61 years 305 exhibited the highest values for blood urea nitrogen (BUN), urea, creatinine (only 306 statistically significant in unvaccinated patients), and D-dimer. In addition, patients in the 307 age groups of <30 and 31-60 showed the highest values for lymphocytes, hematocrit, and 308 albumin (only statistically significant in unvaccinated patients). AstraZeneca (13.3%), and Cansino (11.9%) the most administered (Fig. 3B ). This allowed 317 us to analyze the effect of the different vaccines on the severity of the disease. To isolate 318 the age effect (Suppl. Figure S2 ), we kept only fully vaccinated patients above 61 years old 319 (N=88) and tested for differences in the severity of the disease, O 2 requirement, and 320 severity indexes ( Fig. 3C-E) . Regarding COVID-19 classification, we found that all 321 patients vaccinated with AstraZeneca (N=12) or Cansino (N=7) coursed a severe or critical 322 disease without patients in the mild disease group (Fig. 3C ), although this may be due to 323 small sample sizes. Also, we found the highest proportion of patients with mild disease in 324 the Pfizer group ( Fig. 3C and Suppl. We identified the lineages of 386 (38%) samples by partial or complete genome sequencing 362 (Table 3) . From this subset of samples, we detected VOC such as Alpha (2.3%), Gamma 363 Table S5) . 369 370 Furthermore, we also found differences in the distribution of SARS-CoV-2 lineages 371 between outpatients and hospitalized patients (Table 3 ). In particular, we found the highest 372 proportion of Delta variant in outpatients (82.5%, Chi-square test, p < 0.001), while 373 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. (Fig. 5C) . Furthermore, we found a general increase in the 377 proportion of vaccinated patients during the study period (Fig. 5D) . These temporal 378 variations make complex the analysis of potential associations between disease severity and 379 lineages. It is worth mentioning that the number of critical and severe patients (green and 380 purple colors) seems to decrease as the vaccination increases (Fig. 5D) . Altogether, we 381 found no significant association between disease severity and lineages ( Supplementary Fig. 382 S3). Nonetheless, when analyzing the symptoms associated with patients infected with 383 different lineages, we noted that diarrhea tended to be associated more frequently with 384 B.1.1.519 infections (Fig. 5B) . Mexico started at the end of 2020 and first focused on health care workers before moving 415 on to individuals over 60, 50, and 40 years old in February, May, and June, respectively. As 416 a result, in our cohort, the prevalence of comorbidities was even higher in fully vaccinated 417 patients (Table 1) , with more than 90% presenting at least one comorbidity, and over 75% 418 were older than 60 years of age. Some studies have shown that the presence of 419 comorbidities and advanced ages can also affect vaccines' effectiveness [12] . Moreover, in 420 both COVID-19 [6,22,30] and Influenza disease [31], it has been shown that advanced age 421 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. (Table 2) . Nonetheless, when compared to unvaccinated 426 individuals, the vaccinated group showed the lowest mortality rate (Table 2 ) and required 427 mechanical ventilation less frequently (Fig.1C) . These observations confirm that although 428 the vaccine's protective effect may be reduced in individuals with risk factors, they still 429 provide protection against fatal outcomes. 430 431 Moreover, we found that a significant proportion of patients had either severe or critical 432 outcomes, regardless of age and vaccination status (Fig.1A) . Although this could be a 433 In addition, we analyzed laboratory parameters by vaccination status and age groups. 441 Regardless of the vaccination status, patients older than 61 years exhibited the highest 442 values for BUN, urea, creatinine, and D-dimer (Fig. 2) . This is of special relevance since 443 such parameters are known as markers of disease severity and are commonly found 444 elevated in individuals with acute infections [35] . Moreover, urea, BUN, and creatinine are 445 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. It is important to point out that this study was not designed to assess vaccine effectiveness 452 against COVID-19. However, Mexico is one of the few countries that used seven different 453 vaccines, offering a unique opportunity to compare these vaccine types and to look for 454 differences in severity and/or mortality. In this study, by analyzing solely patients above 61 455 years old we found, in general, a high proportion of critical patients but low mortality rates 456 regardless of the vaccine applied (Suppl . Table S2) Understanding the impact of SARS-CoV-2 lineages on disease severity in both 467 unvaccinated and vaccinated individuals is of major importance, especially since such 468 variants could still emerge due to the evolution pressure driven by the population immunity 469 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. also detected, mainly between May and July 2021 (Fig. 5-6) . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. We determined the main factors that lead to fatal outcomes in our cohort. According to the 499 fitted Generalized Linear Models (GLM) (Fig. 4) , full vaccination was found to be a 500 protective factor against death by COVID-19. On the contrary, platelets <175 x10 9 /l, age 501 above 61 years old, immune disease, D-dimer > 1.8 ug/mL, and lactate dehydrogenase 502 (LDH) above 600 u/L were found as risk factors. Notably, thrombocytopenia and high 503 levels of LDH have been found associated with severe COVID-19 in other studies [48, 49] . 504 Furthermore, contrary to other studies [50] we did identify advanced age as a risk factor 505 itself in COVID-19 patients. It is known that the decline of physiologic functions and the 506 immunosenescence associated with increasing age can negatively affect the host response 507 to infectious diseases [6, 22, 30] . Finally, we hypothesize that complete vaccination may 508 diminish age negative effect since we found that despite that most of the fully vaccinated 509 patients were >61 years old (78%), 83.3% were discharged from the hospital. 510 Our study includes a considerable number of critical and severe patients enrolled, which 512 allowed us to analyze the impact of vaccination, vaccine type, SARS-CoV-2 lineages, and 513 several host factors on mortality and clinical presentation. However, the source is a single 514 referral hospital, and a pandemic wave mostly by the Delta variant, preventing an analysis 515 among vaccination status and lineages. 516 517 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274772 doi: medRxiv preprint Comorbidities and advanced ages were the main risk factors, and complete vaccination 519 schemes with different vaccine types (Pfizer, AstraZeneca, Cansino, SinoVac, and Sputnik) 520 were the most significant protective factor against death by COVID-19. Moreover, we did 521 not find strong associations between a particular lineage (Alpha, Gamma, B.1.1.519, and 522 Delta) and disease severity, highlighting the predominant role of host factors such as age, 523 comorbidities, and vaccination status on COVID-19 outcome. 524 Complete vaccination schemes for the whole population, are key to reducing both 525 hospitalization and death. Nevertheless, public health policy should also focus on the 526 control of comorbidities in the long term, which will improve clinical outcomes not only 527 for COVID-19 but also for other current and emerging diseases. Genomic surveillance is 528 essential to identify circulating VOC, which can help to guide the implementation of 529 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274772 doi: medRxiv preprint Not applicable. 542 The genomic information generated during the current study is available in the GenBank 544 repository, accession numbers: ON158371-ON158443. 545 The clinical datasets used during the current study are available from the corresponding 546 author on reasonable request. 547 The authors declare that they have no competing interests. 549 CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. ; https://doi.org/10.1101/2022.05.06.22274772 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 9, 2022. APACHEII * * E + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A Novel Coronavirus from Patients with 663 Pneumonia in China Organization WH. WHO Coronavirus Disease (COVID-19) Dashboard Evolutionary 666 and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide Snapshot on its genome variants SARS-CoV-2 672 variants, spike mutations and immune escape 676 (Beta), and B.1.617.2 (Delta) Genetic analysis 678 of sars cov 2 variants in mexico during the first year of the covid 19 pandemic epidemilogical, and clinical description of the SARS-CoV-2 omicron variant in Mexico City Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 685 predominantly present in Mexico COVID-19 MÉXICO: Comunicado técnico diario Mexico City Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a 696 systematic review and meta-analysis The great escape? SARS-CoV-2 variants evading neutralizing responses. Cell Host 698 Microbe SARS-CoV-2 Mutations and Their Impact 700 on Diagnostics, Therapeutics and Vaccines CoV-2; consequences in structure, function, and pathogenicity of the virus Effects of SARS-CoV-2 variants on vaccine efficacy 705 and response strategies Phylogenetic analysis of the first 708 four SARS-CoV-2 cases in Chile Molecular evolutionary genetics analysis 710 across computing platforms MAFFT: A novel method for rapid multiple sequence 712 alignment based on fast Fourier transform The Impact of Age Difference on the Efficacy and Safety of COVID-19 715 Vaccines: A Systematic Review and Meta-Analysis R: A language and environment for statistical computing Austria: R 721 Foundation for Statistical Computing ggplot2: Elegant graphics for 723 data analysis Survminer: drawing survival curves using ggplot2. CRAN OpenSAFELY: factors 727 associated with COVID-19 death in 17 million patients Chronic comorbidities and clinical outcomes 729 in patients with and without COVID-19: a large population-based study using national administrative 730 healthcare open data of Mexico Age-related immune response 733 heterogeneity to SARS-CoV-2 vaccine BNT162b2 Effect of vaccination, comorbidities and age on mortality and severe 736 disease associated with influenza during the season 2016-2017 in a Spanish tertiary hospital Public Health X-linked recessive TLR7 740 deficiency in ~ 1 % of men under 60 years old with life-threatening COVID-19 The major genetic risk factor for severe COVID-19 is associated with protection against HIV COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and 746 comorbidities -surveillance results from southern Sweden. medRxiv Acute phase reactants in infections: evidence-based review and a guide for clinician. Open 748 Forum Infect Dis Kidney Injury in Patients With COVID-19 Hypoalbuminemia in COVID-753 19: assessing the hypothesis for underlying pulmonary capillary leakage Clinical course and risk factors for mortality of adult 756 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 vaccination for people with comorbidities Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine 761 Breakthrough Infections Understanding the Secret of SARS-CoV-2 Variants 763 of Concern/Interest and Immune Escape Severity, pathogenicity and transmissibility of delta and lambda 765 variants of SARS-CoV-2, toxicity of spike protein and possibilities for future prevention of COVID-766 19 Differences in Clinical Characteristics Between Delta 768 Variant and Wild-Type SARS-CoV-2 Infected Patients effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 774 variants in the United States: prospective observational study SARS-CoV-2 genomic variation in 776 space and time in hospitalized patients in Philadelphia Genomic Characterization of SARS-CoV-2 Isolated from Patients with Distinct Disease Outcomes in 779 Thrombocytopenia is associated with severe coronavirus disease 2019 781 (COVID-19) infections: A meta-analysis Lactate dehydrogenase levels 784 predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis The Impact of SARS-CoV-2 Primary Vaccination in a Cohort of Patients Hospitalized for Acute COVID-19 during Delta Variant 788 Predominance